PSMC2

Across TCGA pan-cancer cohorts, PSMC2 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of PSMC2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PSMC2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PSMC2 is over-expressed in tumor.

HNSC, CCRCC, and COAD are the cancer types where PSMC2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PSMC2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.206	<.001	11	view →
CCRCC	All	III,IV	+0.120	<.001	11	view →
COAD	Female	III,IV	+0.302	<.001	10	view →
LUAD	Male	II,III,IV	+0.265	<.001	9	view →
LSCC	Male	II,III,IV	+0.344	<.001	8	view →
PDAC	Male	All	+0.283	<.001	7	view →
OV	All	All	+0.300	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

PSMC2–HNSC

Open the HNSC breakdown →